active
ACTIVE SINCE: 2013

Voluntary License for atazanavir & daclatasvir

In the last two decades, we have implemented different strategies to responsibly share Intellectual Property rights for our then flagship HIV/AIDS and Hepatitis C medicines. For example, BMS has entered into voluntary licensing agreements with the Medicines Patent Pool (MPP) for daclatasvir and atazanavir.
SGDS CONTRIBUTING TO:
MEMBER COMPANIES:
Intergovernmental Organizations and Multilaterals 1
  • Bristol Myers Squibb strives to identify downstream solutions that enable the proper delivery and use of sophisticated medicines. In resource-strained contexts where health systems are ready to adopt our medicines, we adapt our supply and distribution approaches in ways which draw on our unique strengths as well as existing local capacity. These include solutions for greater supply capacity such as selective voluntary licensing agreements. In the last two decades, we have implemented different strategies to responsibly share Intellectual Property rights for our then flagship HIV/AIDS medicines. These included not filing or enforcing patent applications in LMICs, supporting voluntary licensing agreements including non-exclusive voluntary licenses, and entering into complementary technology transfer agreements with generic manufacturers to ensure that our medicines are manufactured with internationally recognized standards of Good Manufacturing Practices (GMP). For example, BMS has entered into voluntary licensing agreements with the Medicines Patent Pool (MPP) for daclatasvir and atazanavir.
  • BMS first entered into an agreement with MPP in 2013 to allow for generic manufacturing of the HIV product atazanavir in 110 countries. BMS subsequently signed an extension of the licensing agreement to include 12 additional countries in 2017, allowing generic manufacturing of atazanavir for sale in 122 countries, accounting for 89% of people living with HIV (PLHIV) in LMICs.
  • In 2015, BMS entered into a voluntary licensing agreement with MPP to allow for generic manufacturing of the Hepatitis C product, daclatasvir in 112 countries.
Results and milestones
  • To date, MPP licensees have sold approximately 26 million packs of generic atazanavir/ritonavir across 90 countries, which means 2.1 million patient years of treatment supplied.
  • To date, an additional 31 countries have been added to the covered territory, bringing the total to 143 countries. In 2021, daclatasvir reached approximately 1.2 million patients.
Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
SGDs the partnership contributes to
SDG 3: Good health and well-being
  1. 3.3: Communicable diseases and NTDs
  2. 3.8: Achieve universal health coverage
SDG 17: Partnerships for the goals 
Partner organizations
Intergovernmental Organizations and Multilaterals

Medicines Patent Pool (MPP)

Additional information